Immunitrack is amongst the 65 deep tech SME’s selected to be part of the InvestHorizon accelerator program in the summer 2020 call.
Our company builds on more than twelve years of experience in performing and optimizing in vitro MHC/epitope binding assays for MHC I and MHC II.
Since its founding in 2013, Immunitrack has developed its unique NeoScreen® platform, providing researchers with a better tool for assessing the immunogenicity of epitopes.
Current upscaling project: the company aims to develop a novel T-cell epitope prediction software, called PrDx, which, when combined with currently commercialised reagents and assay services, will represent a very powerful epitope (neoantigen) identification platform.
InvestHorizon sets out to establish and promote an environment of collaboration, support and growth. Its expanding community of committed SMEs, investors and business professionals welcomes new members and helps them raise their visibility so that they find partnerships, expert advice or investment. More information ▸
For further information, please contact:
Stephan Thorgrimsen, CEO